Search research articles
Contact Us
Filters
Showing results (241-250 of 257) with videos related to
Page
of 26
Sort By:
BMC Cancer
|
September 7, 2021
Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study
Gabriel Tremblay, Patrick Daniele, Janis Breeze, et al.
Journal of Hematology & Oncology
|
April 14, 2021
Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma
Maria V Mateos, Maria Gavriatopoulou, Thierry Facon, et al.
Blood
|
September 26, 2018
Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma
Aurore Perrot, Valerie Lauwers-Cances, Jill Corre, et al.
Blood
|
October 13, 2016
Serum free light chains, not urine specimens, should be used to evaluate response in light-chain multiple myeloma
Thomas Dejoie, Jill Corre, Helene Caillon, et al.
Blood
|
March 23, 2016
VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial
Philippe Moreau, Cyrille Hulin, Margaret Macro, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 5, 2019
Carfilzomib Weekly plus Melphalan and Prednisone in Newly Diagnosed Transplant-Ineligible Multiple Myeloma (IFM 2012-03): A Phase I Trial
Xavier Leleu, Guillemette Fouquet, Valentine Richez, et al.
Blood
|
November 19, 2017
Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma
Thierry Facon, Meletios A Dimopoulos, Angela Dispenzieri, et al.
Nature Communications
|
January 17, 2014
Heterogeneity of genomic evolution and mutational profiles in multiple myeloma
Niccolo Bolli, Hervé Avet-Loiseau, David C Wedge, et al.
The Lancet. Oncology
|
June 18, 2024
Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial
Philippe Moreau, Cyrille Hulin, Aurore Perrot, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 29, 2021
Minimal Residual Disease in Myeloma: Application for Clinical Care and New Drug Registration
Kenneth C Anderson, Daniel Auclair, Stacey J Adam, et al.
Page
of 26
Search research articles
Search
Showing results (241-250 of 257) with videos related to
Sort By:
Page
of 26
BMC Cancer
|
September 7, 2021
Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study
Gabriel Tremblay, Patrick Daniele, Janis Breeze, et al.
Journal of Hematology & Oncology
|
April 14, 2021
Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma
Maria V Mateos, Maria Gavriatopoulou, Thierry Facon, et al.
Blood
|
September 26, 2018
Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma
Aurore Perrot, Valerie Lauwers-Cances, Jill Corre, et al.
Blood
|
October 13, 2016
Serum free light chains, not urine specimens, should be used to evaluate response in light-chain multiple myeloma
Thomas Dejoie, Jill Corre, Helene Caillon, et al.
Blood
|
March 23, 2016
VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial
Philippe Moreau, Cyrille Hulin, Margaret Macro, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 5, 2019
Carfilzomib Weekly plus Melphalan and Prednisone in Newly Diagnosed Transplant-Ineligible Multiple Myeloma (IFM 2012-03): A Phase I Trial
Xavier Leleu, Guillemette Fouquet, Valentine Richez, et al.
Blood
|
November 19, 2017
Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma
Thierry Facon, Meletios A Dimopoulos, Angela Dispenzieri, et al.
Nature Communications
|
January 17, 2014
Heterogeneity of genomic evolution and mutational profiles in multiple myeloma
Niccolo Bolli, Hervé Avet-Loiseau, David C Wedge, et al.
The Lancet. Oncology
|
June 18, 2024
Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial
Philippe Moreau, Cyrille Hulin, Aurore Perrot, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 29, 2021
Minimal Residual Disease in Myeloma: Application for Clinical Care and New Drug Registration
Kenneth C Anderson, Daniel Auclair, Stacey J Adam, et al.
Page
of 26